Standout Papers

Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung o... 2022 2026 2023 2024217
  1. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial (2022)
    Vivek Subbiah, Jürgen Wolf et al. The Lancet Oncology

Immediate Impact

18 standout
Sub-graph 1 of 7

Citing Papers

FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
2024 Standout
New clinical trial design in precision medicine: discovery, development and direction
2024 Standout
1 intermediate paper

Works of Loretta Sullivan being referenced

Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial
2022 Standout

Author Peers

Author Last Decade Papers Cites
Loretta Sullivan 97 146 6 105 4 230
A Charbit 106 130 2 57 6 290
Leonard M. Holtegaard 74 113 9 69 7 298
Maribel Mármol 29 173 81 8 275
April Fritz 53 131 67 7 222
Christina Zander 90 163 156 4 267
J. Morreau 86 189 1 58 7 287
S G Taylor 66 142 65 7 283
Victoria Williams 76 67 3 98 7 203
Farida Mesli 54 114 1 73 5 228
J. Selleslags 64 194 72 7 243

All Works

Loading papers...

Rankless by CCL
2026